This symposium, jointly hosted by the Royal Society and Academy of Medical Sciences, will explore innovative, evidence-based health technologies and interventions that can benefit women during the different stages of their lives.
In the UK, 51% of the population and 47% of the workforce are women, yet the funding for research of women’s health is much less than for research of men’s health issues. The resulting unmet health needs of women present a major health inequality but also a significant market opportunity for gendered innovation. Recent appreciation of this has led to a surge of investment into new technologies and treatments in the women’s health sector, including the ongoing growth of a $35bn ‘fem tech’ market. Many such innovations offer exciting opportunities for a personalised and preventive approach to women’s health across a life course, but it is critical that these advances are evidence-based and inclusive, to maximise benefits to women and avoid unintentional harms.
This meeting will explore some novel health interventions that support women to live healthily through the major transitions of their life. Speakers will discuss examples of innovative research, therapies and technologies that benefit women’s health and consider how to overcome some of the societal challenges and barriers to building systems, in healthcare and beyond, that meet the needs of all women at different stages of their lives.
About the conference series
Supported by AstraZeneca, the meeting will form part of the Royal Society’s Transforming our future conferences in the life sciences, and the Academy of Medical Sciences’ FORUM programme. These meetings are unique, high-level events that address the scientific and technical challenges of the next decade. Each conference features cutting edge science from industry and academia and brings together leading experts from the scientific community, including regulatory, charity and funding bodies.